DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia

Wellcome Trust Case Control Consortium 2

Research output: Contribution to journalArticlepeer-review

72 Citations (Scopus)
24 Downloads (Pure)

Abstract

We performed a systematic analysis of blood DNA methylation profiles from 4,483 participants from seven independent cohorts identifying differentially methylated positions (DMPs) associated with psychosis, schizophrenia and treatment-resistant schizophrenia. Psychosis cases were characterized by significant differences in measures of blood cell proportions and elevated smoking exposure derived from the DNA methylation data, with the largest differences seen in treatment-resistant schizophrenia patients. We implemented a stringent pipeline to meta-analyze epigenome-wide association study (EWAS) results across datasets, identifying 95 DMPs associated with psychosis and 1,048 DMPs associated with schizophrenia, with evidence of colocalization to regions nominated by genetic association studies of disease. Many schizophrenia-associated DNA methylation differences were only present in patients with treatment-resistant schizophrenia, potentially reflecting exposure to the atypical antipsychotic clozapine. Our results highlight how DNA methylation data can be leveraged to identify physiological (e.g., differential cell counts) and environmental (e.g., smoking) factors associated with psychosis and molecular biomarkers of treatment-resistant schizophrenia.

Original languageEnglish
Article numbere58430
Pages (from-to)1-53
Number of pages53
JournaleLife
Volume10
Early online date26 Feb 2021
DOIs
Publication statusPublished - Feb 2021

Fingerprint

Dive into the research topics of 'DNA methylation meta-analysis reveals cellular alterations in psychosis and markers of treatment-resistant schizophrenia'. Together they form a unique fingerprint.

Cite this